Health Catalyst (HCAT)
Health Catalyst on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as services-computer programming, data processing, etc..
2.2M
Short interest
settlement 2026-09-30
5.2
Days to cover
+1.3 days vs prior
13.2%
Short share of volume
2026-10-13
84
Fails to deliver
settlement 2026-08-28
Mon 9 Nov
Next earnings
estimated date
$105K
Insider flow, 90 days
1 buys, 0 sells
As of 2026-10-13.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in HCAT is 2,212,809 shares, up 261,424 shares over the last month. Over the last 48 readings it ranged from 1,951,385 shares (31 August 2026) to 7,686,596 shares (31 March 2026). The latest reading sits at the bottom of that range. At the reported average volume of 426K shares a day that is 5.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/hcat" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 2,212,809 | +9.1% | 425,909 | 5.20 |
| 2026-09-15 | 2,028,738 | +4.0% | 516,664 | 3.93 |
| 2026-08-31 | 1,951,385 | -14.8% | 477,347 | 4.09 |
| 2026-08-14 | 2,290,367 | -23.3% | 1,395,651 | 1.64 |
| 2026-07-31 | 2,986,245 | -18.1% | 493,067 | 6.06 |
| 2026-07-15 | 3,645,405 | -20.7% | 965,372 | 3.78 |
| 2026-06-30 | 4,597,012 | -27.6% | 2,166,281 | 2.12 |
| 2026-06-15 | 6,349,157 | -3.6% | 4,071,420 | 1.56 |
| 2026-05-29 | 6,585,307 | -8.7% | 531,628 | 12.39 |
| 2026-05-15 | 7,208,853 | -5.0% | 643,628 | 11.20 |
| 2026-04-30 | 7,584,789 | +0.4% | 546,784 | 13.87 |
| 2026-04-15 | 7,556,239 | -1.7% | 603,932 | 12.51 |
| 2026-03-31 | 7,686,596 | +4.4% | 860,019 | 8.94 |
| 2026-03-13 | 7,363,089 | +9.1% | 1,027,541 | 7.17 |
| 2026-02-27 | 6,750,287 | +18.1% | 1,060,809 | 6.36 |
| 2026-02-13 | 5,716,947 | +14.4% | 904,479 | 6.32 |
| 2026-01-30 | 4,996,968 | -1.4% | 628,365 | 7.95 |
| 2026-01-15 | 5,065,830 | +0.3% | 520,744 | 9.73 |
| 2025-12-31 | 5,050,847 | -3.3% | 558,630 | 9.04 |
| 2025-12-15 | 5,223,498 | -13.3% | 726,349 | 7.19 |
| 2025-11-28 | 6,028,208 | -0.5% | 782,844 | 7.70 |
| 2025-11-14 | 6,060,201 | -2.3% | 805,656 | 7.52 |
| 2025-10-31 | 6,203,840 | -6.5% | 552,093 | 11.24 |
| 2025-10-15 | 6,632,700 | +0.5% | 429,229 | 15.45 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 13 October 2026, the short share of HCAT volume is 13.2%, down 34.2 points over the last five sessions. Over the last 30 readings it ranged from 10.0% (12 October 2026) to 74.5% (10 September 2026). The latest reading sits at the bottom of that range. The latest reading is 33.5 points below the 30-session average of 46.6%, on 498K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-13 | 66K | 498K | 13.2% | 613 |
| 2026-10-12 | 14K | 136K | 10.0% | 0 |
| 2026-10-09 | 53K | 408K | 13.0% | 2,423 |
| 2026-10-08 | 65K | 182K | 35.8% | 1,199 |
| 2026-10-07 | 46K | 80K | 57.1% | 0 |
| 2026-10-06 | 43K | 91K | 47.4% | 0 |
| 2026-10-05 | 41K | 91K | 45.3% | 0 |
| 2026-10-02 | 40K | 67K | 60.3% | 0 |
| 2026-10-01 | 59K | 148K | 40.1% | 0 |
| 2026-09-30 | 68K | 125K | 54.9% | 4 |
| 2026-09-29 | 68K | 97K | 70.5% | 122 |
| 2026-09-28 | 106K | 207K | 51.3% | 501 |
| 2026-09-25 | 10K | 29K | 33.3% | 0 |
| 2026-09-24 | 125K | 209K | 59.8% | 5,001 |
| 2026-09-23 | 18K | 57K | 32.5% | 1 |
| 2026-09-22 | 45K | 86K | 52.5% | 448 |
| 2026-09-21 | 48K | 98K | 48.8% | 595 |
| 2026-09-18 | 46K | 68K | 66.7% | 0 |
| 2026-09-17 | 52K | 167K | 30.9% | 1 |
| 2026-09-16 | 60K | 118K | 51.1% | 0 |
| 2026-09-15 | 57K | 92K | 61.4% | 7 |
| 2026-09-14 | 113K | 317K | 35.8% | 0 |
| 2026-09-11 | 40K | 82K | 49.1% | 0 |
| 2026-09-10 | 154K | 207K | 74.5% | 313 |
| 2026-09-09 | 112K | 175K | 63.9% | 0 |
| 2026-09-08 | 152K | 259K | 58.6% | 0 |
| 2026-09-04 | 57K | 167K | 34.2% | 6,600 |
| 2026-09-03 | 37K | 89K | 41.9% | 0 |
| 2026-09-02 | 79K | 189K | 41.6% | 0 |
| 2026-09-01 | 116K | 183K | 63.7% | 4,135 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 28 August 2026, the fails-to-deliver balance in HCAT is 84 shares, down 5,847 shares over the last settlement date. Over the last 30 readings it ranged from 7 shares (18 June 2026) to 21,005 shares (28 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-28 | 84 | $1.59 | $134 |
| 2026-08-21 | 5,931 | $1.63 | $10K |
| 2026-07-31 | 717 | $2.08 | $1K |
| 2026-07-23 | 82 | $2.04 | $167 |
| 2026-07-20 | 100 | $2.25 | $225 |
| 2026-07-17 | 10 | $2.28 | $23 |
| 2026-07-15 | 302 | $2.29 | $692 |
| 2026-07-08 | 3,999 | $2.27 | $9K |
| 2026-07-07 | 696 | $2.29 | $2K |
| 2026-07-02 | 4,878 | $2.07 | $10K |
| 2026-07-01 | 502 | $1.99 | $999 |
| 2026-06-29 | 7,804 | $1.90 | $15K |
| 2026-06-22 | 5,937 | $1.74 | $10K |
| 2026-06-18 | 7 | $1.77 | $12 |
| 2026-06-10 | 230 | $1.71 | $393 |
| 2026-06-09 | 9,200 | $1.75 | $16K |
| 2026-06-08 | 2,572 | $1.93 | $5K |
| 2026-06-02 | 500 | $1.39 | $695 |
| 2026-05-28 | 549 | $1.30 | $714 |
| 2026-05-22 | 9,333 | $1.29 | $12K |
| 2026-05-15 | 6,987 | $1.17 | $8K |
| 2026-05-14 | 1,629 | $1.34 | $2K |
| 2026-05-13 | 2,102 | $1.48 | $3K |
| 2026-05-12 | 1,336 | $1.38 | $2K |
| 2026-05-11 | 802 | $1.52 | $1K |
| 2026-05-08 | 1,211 | $1.59 | $2K |
| 2026-05-06 | 100 | $1.60 | $160 |
| 2026-04-28 | 21,005 | $1.37 | $29K |
| 2026-04-15 | 367 | $1.12 | $411 |
| 2026-04-14 | 1,199 | $1.06 | $1K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at HCAT reported 1 open-market buy worth $105K in the last 90 days and no open-market sells. Latest filing: Reller Tami (Director) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Reller Tami | Director | Grant | 129K | $0.00 | $0 | 129K |
| 2026-09-14 | Kohl Simeon | Chief Executive Officer | Buy | 59K | $1.79 | $105K | 2.9M |
| 2026-09-14 | Kohl Simeon | Chief Executive Officer | Grant | 2.7M | $0.00 | $0 | 2.8M |
| 2026-09-10 | Albert Benjamin | CEO | Tax withholding | 35K | $1.67 | $59K | 1.4M |
| 2026-09-01 | Landry Benjamin | General Counsel | Tax withholding | 13K | $1.70 | $22K | 351K |
| 2026-09-01 | Larson-Green Julie | Director | Grant | 10K | $0.00 | $0 | 185K |
| 2026-09-01 | Alger Jason | Chief Financial Officer | Tax withholding | 18K | $1.70 | $31K | 705K |
| 2026-09-01 | Albert Benjamin | CEO | Tax withholding | 321 | $1.70 | $547 | 1.4M |
| 2026-07-16 | Hoggard Green Jill | Director | Grant | 81K | $0.00 | $0 | 145K |
| 2026-07-16 | Larson-Green Julie | Director | Grant | 81K | $0.00 | $0 | 175K |
| 2026-07-16 | Spencer Justin | Director | Grant | 81K | $0.00 | $0 | 149K |
| 2026-07-16 | Nelson Steven H | Director | Grant | 81K | $0.00 | $0 | 235K |
| 2026-06-10 | Albert Benjamin | CEO | Tax withholding | 34K | $1.69 | $58K | 1.4M |
| 2026-06-01 | Landry Benjamin | General Counsel | Tax withholding | 14K | $1.37 | $19K | 365K |
| 2026-06-01 | Larson-Green Julie | Director | Grant | 13K | $0.00 | $0 | 95K |
| 2026-06-01 | Llewelyn Linda | Chief People Officer | Tax withholding | 9K | $1.37 | $12K | 321K |
| 2026-06-01 | Alger Jason | Chief Financial Officer | Tax withholding | 19K | $1.37 | $26K | 723K |
| 2026-06-01 | Albert Benjamin | CEO | Tax withholding | 336 | $1.37 | $460 | 1.5M |
| 2026-05-01 | Albert Benjamin | CEO | Tax withholding | 310 | $1.34 | $417 | 1.5M |
| 2026-05-01 | Nelson Steven H | Director | Grant | 155K | $0.00 | $0 | 155K |
| 2026-04-29 | Albert Benjamin | CEO | Grant | 1K | $0.00 | $0 | 1.5M |
| 2026-03-10 | Albert Benjamin | CEO | Tax withholding | 70K | $1.85 | $130K | 1.5M |
| 2026-03-02 | Landry Benjamin | General Counsel | Tax withholding | 21K | $1.66 | $35K | 378K |
| 2026-03-02 | Llewelyn Linda | Chief People Officer | Tax withholding | 14K | $1.66 | $23K | 330K |
| 2026-03-02 | Alger Jason | Chief Financial Officer | Tax withholding | 27K | $1.66 | $45K | 742K |
| 2026-03-02 | Albert Benjamin | CEO | Tax withholding | 5K | $1.66 | $8K | 1.5M |
| 2026-03-01 | Larson-Green Julie | Director | Grant | 8K | $0.00 | $0 | 82K |
| 2026-02-26 | Landry Benjamin | General Counsel | Tax withholding | 6K | $1.75 | $11K | 399K |
| 2026-02-26 | Llewelyn Linda | Chief People Officer | Tax withholding | 4K | $1.75 | $8K | 343K |
| 2026-02-26 | Alger Jason | Chief Financial Officer | Tax withholding | 8K | $1.75 | $13K | 769K |
| 2026-02-26 | Albert Benjamin | CEO | Tax withholding | 13K | $1.75 | $23K | 1.5M |
| 2026-02-25 | Landry Benjamin | General Counsel | Grant | 16K | $0.00 | $0 | 405K |
| 2026-02-25 | Landry Benjamin | General Counsel | Grant | 289K | $0.00 | $0 | 389K |
| 2026-02-25 | Llewelyn Linda | Chief People Officer | Grant | 13K | $0.00 | $0 | 348K |
| 2026-02-25 | Llewelyn Linda | Chief People Officer | Grant | 192K | $0.00 | $0 | 335K |
| 2026-02-25 | Alger Jason | Chief Financial Officer | Grant | 22K | $0.00 | $0 | 776K |
| 2026-02-25 | Alger Jason | Chief Financial Officer | Grant | 508K | $0.00 | $0 | 754K |
| 2026-02-25 | Albert Benjamin | CEO | Grant | 39K | $0.00 | $0 | 1.5M |
| 2026-02-25 | Albert Benjamin | CEO | Grant | 930K | $0.00 | $0 | 1.5M |
| 2026-02-17 | Gallagher Duncan | Director | Grant | 8K | $0.00 | $0 | 132K |
| 2025-12-05 | Landry Benjamin | General Counsel | Sell | 27K | $2.64 | $72K | 100K |
| 2025-12-04 | Larson-Green Julie | Director | Sell | 48K | $2.67 | $128K | 74K |
| 2025-12-01 | Landry Benjamin | General Counsel | Tax withholding | 14K | $2.90 | $42K | 127K |
| 2025-12-01 | Larson-Green Julie | Director | Grant | 6K | $0.00 | $0 | 122K |
| 2025-12-01 | Llewelyn Linda | Chief People Officer | Tax withholding | 10K | $2.90 | $28K | 143K |
| 2025-12-01 | Gallagher Duncan | Director | Grant | 6K | $0.00 | $0 | 124K |
| 2025-12-01 | Freeman Kevin Lee | Chief Commercial Officer | Tax withholding | 16K | $2.90 | $48K | 359K |
| 2025-12-01 | Burton Daniel D. | Chief Executive Officer | Tax withholding | 56K | $2.90 | $162K | 1.4M |
| 2025-12-01 | Alger Jason | Chief Financial Officer | Tax withholding | 21K | $2.90 | $60K | 246K |
| 2025-09-24 | Albert Benjamin | President and COO | Grant | 467K | $0.00 | $0 | 578K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON21 Form 144 notices on file for HCAT worth $982K at the prices reported; 0 in the last 90 days worth $0. Latest: Benjamin Albert filed on 2026-03-10 to sell 70,455 shares ($130K) from 2026-03-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-03-10 | Benjamin AlbertOfficer | 70K | $130K | 0.100% | 2026-03-10 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Linda LlewelynOfficer | 14K | $23K | 0.020% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Benjamin LandryOfficer | 21K | $35K | 0.029% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Kevin FreemanOther | 16K | $26K | 0.022% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Daniel BurtonOther | 26K | $43K | 0.036% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Jason AlgerOfficer | 27K | $45K | 0.038% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Benjamin AlbertOfficer | 5K | $8K | 0.007% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Benjamin LandryOfficer | 6K | $11K | 0.009% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Linda LlewelynOfficer | 4K | $8K | 0.006% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Kevin FreemanOther | 7K | $12K | 0.009% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Daniel BurtonOther | 29K | $50K | 0.041% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Jason AlgerOfficer | 8K | $13K | 0.011% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2026-02-26 | Benjamin AlbertOfficer | 13K | $23K | 0.019% | 2026-02-26 | Morgan Stanley Smith Barney LLC |
| 2025-12-05 | BENJAMIN LANDRYOfficer | 27K | $74K | 0.039% | 2025-12-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | JULIE LARSON-GREENDirector | 48K | $128K | 0.068% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | David RossOfficer | 5K | $14K | 0.007% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Linda LlewellynOfficer | 10K | $28K | 0.014% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Benjamin LandryOfficer | 14K | $42K | 0.020% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Kevin FreemanOfficer | 16K | $48K | 0.023% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Daniel BurtonOfficer | 56K | $162K | 0.079% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Jason AlgerOfficer | 21K | $60K | 0.029% | 2025-12-01 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of HCAT in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is Mathew P. Arens at 18.3% of the class (13,465,373 shares), filed 2026-03-13 for an event on 2026-03-12.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-08 | 13D/Ano. 1 | Palogic Value Management, LPinvestment adviser, parent holding company, partnership | 5.4M | 7.1% | 2026-09-04 |
| 2026-09-08 | 13D/Ano. 1 | Palogic Value Fund, LPpartnership | 5.4M | 7.1% | 2026-09-04 |
| 2026-09-08 | 13D/Ano. 1 | Palogic Capital Management, LLCparent holding company, other entity | 5.4M | 7.1% | 2026-09-04 |
| 2026-09-08 | 13D/Ano. 1 | Ryan L. Vardemanindividual, parent holding company | 5.4M | 7.1% | 2026-09-04 |
| 2026-08-14 | 13G/Ano. 2 | COGHILL CLINT Dindividual | 7.1M | 9.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | CDC Financial, Inc.corporation | 7.1M | 9.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Stoney Lonesome HF LPpartnership | 6.8M | 9.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | COGHILL CAPITAL MANAGEMENT LLCother entity | 6.8M | 9.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Drake Helix Holdings, LLCother entity | 320K | 0.4% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 1.1M | 1.5% | 2026-06-30 |
| 2026-07-21 | 13G | Impax Asset Management Group plcparent holding company | 4.0M | 5.4% | 2026-06-30 |
| 2026-07-21 | 13G | IMPAX ASSET MANAGEMENT LLCinvestment adviser | 4.0M | 5.4% | 2026-06-30 |
| 2026-06-08 | 13D/Ano. 2 | David Atterburyparent holding company, insurance company | 3.3M | 4.5% | 2026-06-04 |
| 2026-06-08 | 13D/Ano. 2 | Whetstone Capital Advisors, LLCinvestment adviser, other entity | 3.3M | 4.5% | 2026-06-04 |
| 2026-03-27 | 13G/Ano. 8 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-13 | 13D/Ano. 1 | Mathew P. Arensindividual, parent holding company | 13.5M | 18.3% | 2026-03-12 |
| 2026-03-13 | 13D/Ano. 1 | First Light Asset Management, LLCinvestment adviser | 12.9M | 17.5% | 2026-03-12 |
13F holders
Tracked managers holding HCAT at their latest 13F. JSON5 of the 30 tracked managers held HCAT at their latest 13F, $3.4M in total at quarter-end prices. Millennium Management is the largest at $1.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 516K | $1.0M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 453K | $902K | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 377K | $749K | 0.00% | -167K |
| Renaissance Technologies | 2026-06-30 | 349K | $695K | 0.00% | +132K |
| Two Sigma Investments | 2026-06-30 | 14K | $27K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Health Catalyst reported revenue of $70.5M, down 12.7% from the same quarter a year earlier, and net loss of $40.5M (-0.55 diluted EPS). In FY 2025 it generated $731K of operating cash flow and spent $5.0M on buybacks. As of 2026-06-30, cash was $60.6M against $153.5M of debt.
- Cash
- $60.6M
- Debt
- $153.5M
- Equity
- $100.8M
- Total assets
- $358.6M
- Shares outstanding
- 75,256,381
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $70.5M | -$40.5M | -57.5% | -0.55 |
| Q1 FY 2026 | 2026-03-31 | $70.8M | -$111.0M | -156.9% | -1.53 |
| Q4 FY 2025derived | 2025-12-31 | $74.7M | -$91.0M | -121.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $76.3M | -$22.2M | -29.1% | -0.32 |
| Q2 FY 2025 | 2025-06-30 | $80.7M | -$41.0M | -50.8% | -0.59 |
| Q1 FY 2025 | 2025-03-31 | $79.4M | -$23.7M | -29.9% | -0.35 |
| Q4 FY 2024derived | 2024-12-31 | $79.6M | -$20.7M | -26.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $76.4M | -$14.7M | -19.3% | -0.24 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $311.1M | -$178.0M | $731K | $968K | $5.0M | n/a |
| FY 2024 | 2024-12-31 | $306.6M | -$69.5M | $14.6M | $1.6M | $0 | n/a |
| FY 2023 | 2023-12-31 | $295.9M | -$118.1M | -$33.1M | $1.2M | $1.8M | n/a |
| FY 2022 | 2022-12-31 | $276.2M | -$137.4M | -$35.3M | $2.2M | $8.4M | n/a |
| FY 2021 | 2021-12-31 | $241.9M | -$153.2M | -$23.1M | $10.4M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Health Catalyst in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Health Catalyst (HCAT), SEC CIK 1636422, listed on Nasdaq, classified by the SEC as services-computer programming, data processing, etc.. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-13.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-03-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1636422Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-computer programming, data processing, etc.
- GOOGAlphabet
- METAMeta Platforms
- ZMZoom Communications
- APPAppLovin
- TTDTrade Desk
- PINSPinterest
- GOOGLAlphabet
- EVEREverQuote
- PUBMPubMatic
- ZIPZiprecruiter
- CDLXCardlytics
- DVDoubleVerify Holdings
- SNAPSnap
- MTCHMatch Group
- TRIPTripAdvisor
- TEMTempus AI
- MGNIMagnite
- FDSFactSet Research Systems
- DOCNDigitalOcean Holdings
- BMBLBumble
- HSTMHealthstream
- BLNDBlend Labs
- SABRSabre
- TBLATaboola.com
Datasets
Frequently Asked Questions
How much of HCAT is sold short?
What is HCAT's daily short volume?
Does HCAT have fails to deliver?
Are HCAT insiders buying or selling?
Have HCAT insiders filed to sell?
Who owns 5% or more of HCAT?
What did HCAT report last quarter?
Which tracked 13F managers own HCAT?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.